SK Biopharmaceuticals Co Ltd banner

SK Biopharmaceuticals Co Ltd
KRX:326030

Watchlist Manager
SK Biopharmaceuticals Co Ltd Logo
SK Biopharmaceuticals Co Ltd
KRX:326030
Watchlist
Price: 102 900 KRW -3.47%
Market Cap: ₩8.1T

Income Statement

Earnings Waterfall
SK Biopharmaceuticals Co Ltd

Income Statement
SK Biopharmaceuticals Co Ltd

Rotate your device to view
Income Statement
Currency: KRW
Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024 Jun-2024 Sep-2024 Dec-2024 Mar-2025 Jun-2025 Sep-2025
Revenue
Interest Expense
1 547
2 550
4 450
4 848
4 462
3 651
1 889
1 304
947
941
1 104
2 283
3 717
5 261
6 692
7 540
8 280
8 787
9 992
10 428
10 683
10 930
10 014
9 017
Revenue
123 852
N/A
10 717
-91%
6 274
-41%
10 115
+61%
25 999
+157%
162 060
+523%
183 964
+14%
203 992
+11%
418 645
+105%
319 801
-24%
349 264
+9%
414 148
+19%
246 179
-41%
265 819
+8%
289 399
+9%
290 903
+1%
354 892
+22%
408 082
+15%
465 064
+14%
511 328
+10%
547 596
+7%
577 999
+6%
620 280
+7%
675 406
+9%
Gross Profit
Cost of Revenue
(514)
(916)
(1 653)
(1 985)
(1 974)
(3 419)
(4 693)
(6 581)
(22 336)
(26 501)
(32 372)
(43 390)
(37 768)
(35 695)
(37 114)
(30 671)
(34 082)
(42 090)
(41 461)
(51 198)
(43 101)
(41 654)
(42 813)
(33 828)
Gross Profit
123 338
N/A
9 801
-92%
4 621
-53%
8 130
+76%
24 025
+196%
158 641
+560%
179 271
+13%
197 410
+10%
396 309
+101%
293 300
-26%
316 893
+8%
370 758
+17%
208 411
-44%
230 124
+10%
252 285
+10%
260 232
+3%
320 809
+23%
365 992
+14%
423 603
+16%
460 130
+9%
504 495
+10%
536 345
+6%
577 467
+8%
641 578
+11%
Operating Income
Operating Expenses
(202 597)
(229 844)
(242 143)
(258 168)
(263 524)
(257 090)
(284 966)
(290 007)
(301 350)
(311 411)
(309 995)
(323 169)
(339 489)
(346 720)
(331 569)
(357 157)
(358 331)
(370 562)
(383 192)
(392 831)
(408 156)
(424 629)
(429 914)
(443 263)
Selling, General & Administrative
(22 615)
(56 682)
(83 883)
(96 759)
(145 577)
(139 715)
(157 325)
(161 995)
(176 567)
(187 007)
(184 412)
(195 744)
(205 113)
(209 192)
(210 195)
(211 829)
(208 771)
(213 411)
(213 910)
(220 251)
(234 124)
(243 986)
(253 231)
(264 779)
Research & Development
(176 213)
(168 619)
(154 556)
(155 759)
(108 441)
(75 948)
(85 702)
(86 397)
(113 142)
(113 560)
(114 122)
(115 247)
(121 392)
(124 316)
(124 018)
(131 158)
(134 243)
(140 843)
(152 149)
(151 953)
(156 604)
(164 095)
(160 104)
(162 226)
Depreciation & Amortization
(3 769)
(4 544)
(5 653)
(7 627)
(9 506)
(10 245)
(10 755)
(10 432)
(11 642)
(10 844)
(11 460)
(12 178)
(12 984)
(13 212)
(13 532)
(14 170)
(15 317)
(16 309)
(17 132)
(17 459)
(17 428)
(16 548)
(16 579)
(16 258)
Other Operating Expenses
0
0
1 949
1 977
0
(31 183)
(31 183)
(31 183)
0
0
0
0
0
0
16 176
0
0
0
0
(3 168)
0
0
0
0
Operating Income
(79 259)
N/A
(220 043)
-178%
(237 523)
-8%
(250 039)
-5%
(239 499)
+4%
(98 450)
+59%
(105 695)
-7%
(92 597)
+12%
94 958
N/A
(18 111)
N/A
6 898
N/A
47 588
+590%
(131 078)
N/A
(116 596)
+11%
(79 285)
+32%
(96 925)
-22%
(37 522)
+61%
(4 570)
+88%
40 411
N/A
67 299
+67%
96 340
+43%
111 716
+16%
147 553
+32%
198 315
+34%
Pre-Tax Income
Interest Income Expense
(2 645)
(2 290)
(2 519)
(2 101)
140
4 214
5 089
10 021
(72 438)
(73 709)
(76 774)
(89 725)
(15 452)
(9 554)
(11 375)
(9 381)
(11 486)
(21 900)
(20 018)
(24 425)
(24 615)
(26 816)
(50 385)
(45 315)
Non-Reccuring Items
0
0
0
0
0
50 350
50 350
50 350
49 269
(824)
(824)
(824)
4 317
16 176
0
12 536
5 308
(6 808)
(6 808)
0
0
0
0
593
Gain/Loss on Disposition of Assets
(2 007)
(2 007)
0
(2 007)
(0)
(3)
(3)
(3)
(3)
0
(9)
(10)
(11)
0
(12)
(12)
(19)
0
162
162
171
171
(8)
(19)
Total Other Income
(541)
(248)
(1 816)
(519)
(550)
(570)
(1 032)
(520)
(509)
(450)
(413)
(269)
(245)
21
(44)
(139)
(139)
(327)
1 494
1 531
700
103
(1 104)
(4 909)
Pre-Tax Income
(84 451)
N/A
(224 589)
-166%
(241 858)
-8%
(254 666)
-5%
(239 909)
+6%
(44 459)
+81%
(51 290)
-15%
(32 749)
+36%
71 277
N/A
(93 095)
N/A
(71 123)
+24%
(43 239)
+39%
(142 469)
-229%
(109 953)
+23%
(90 715)
+17%
(93 921)
-4%
(43 858)
+53%
(33 605)
+23%
15 243
N/A
44 568
+192%
72 596
+63%
85 174
+17%
96 055
+13%
148 666
+55%
Net Income
Tax Provision
12 932
12 045
12 321
12 299
(7 504)
(7 369)
(7 905)
(7 647)
(6 431)
(6 255)
(6 634)
(5 206)
3 038
3 359
6 182
5 936
8 478
10 293
9 345
4 742
154 378
151 724
145 810
158 257
Income from Continuing Operations
(71 519)
(212 544)
(229 537)
(242 367)
(247 414)
(51 828)
(59 196)
(40 396)
64 846
(99 351)
(77 756)
(48 445)
(139 431)
(106 594)
(84 533)
(87 985)
(35 379)
(23 313)
24 588
49 310
226 973
236 898
241 865
306 923
Income to Minority Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4 483
2 497
5 631
9 209
8 072
13 765
14 312
14 127
13 550
Net Income (Common)
(71 519)
N/A
(212 544)
-197%
(229 537)
-8%
(242 367)
-6%
(247 414)
-2%
(51 828)
+79%
(59 196)
-14%
(40 396)
+32%
64 846
N/A
(99 351)
N/A
(77 756)
+22%
(48 445)
+38%
(139 431)
-188%
(106 594)
+24%
(84 533)
+21%
(83 502)
+1%
(32 883)
+61%
(17 682)
+46%
33 796
N/A
57 383
+70%
240 738
+320%
251 211
+4%
255 991
+2%
320 473
+25%
EPS (Diluted)
-1 100.3
N/A
-3 269.9
-197%
-3 531.33
-8%
-3 107.26
+12%
-3 447.52
-11%
-661.8
+81%
-755.88
-14%
-515.82
+32%
828.03
N/A
-1 268.63
N/A
-992.89
+22%
-618.6
+38%
-1 780.43
-188%
-1 361.12
+24%
-1 079.42
+21%
-1 066.26
+1%
-419.89
+61%
-225.79
+46%
431.55
N/A
732.73
+70%
3 074.04
+320%
3 207.77
+4%
3 268.81
+2%
4 092.19
+25%
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett